Products are developed on chinese hamster overy (CHO) based mammalian platform using recombinant DNA technology.

Innovative process developed in-house with the proprietary DNA Vectors having novel genetic elements in-licensed from a Swiss company enable scientific rigor with speed to develop highly-comparable biosimilars.

Having developed the clone in-house with well understood characteristics and intricacies of the host system, it’s one of the great strengths enabling Clonz to have the complete control over the manufacturing process in the future.